Leonard G. Gomella, MD

home / authors / leonard-g-gomella-md

Articles

Raoul S. Concepcion, MD, FACS;Jason M. Hafron, MD, CMO;Daniel P. Petrylak, MD;Oliver Sartor, MD;Leonard G. Gomella, MD

November 24th 2021

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

Role of conventional imaging vs PSMA-PET in mCNPC

Raoul S. Concepcion, MD, FACS;Jason M. Hafron, MD, CMO;Daniel P. Petrylak, MD;Oliver Sartor, MD;Leonard G. Gomella, MD

November 24th 2021

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

Therapeutic layering in advanced PCa: Another win

Leonard G. Gomella, MD

May 20th 2019

"Therapeutic layering... is now becoming commonplace in the initial treatment of newly diagnosed metastatic prostate cancer," writes Leonard G. Gomella, MD.

Rethinking race and prostate cancer outcomes

Leonard G. Gomella, MD

October 11th 2018

"Two provocative studies reported at the 2018 ASCO annual meeting provide additional insight into prostate cancer racial disparities in a different group of patients, namely men with advanced prostate cancer who participated in a variety of clinical trials," writes Leonard G. Gomella, MD.

The cost of prostate Ca care: What counts for AS?

Leonard G. Gomella, MD

May 10th 2018

"AS is very cost effective over the short term compared to prostatectomy and radiation, but there a number of factors may impact actual AS cost savings over the long term," writes Leonard G. Gomella, MD.